Evidence and practice regarding the role for CYP2D6 inhibition in decisions about tamoxifen therapy.
Lash
Timothy L
TL
Rosenberg
Carol L
CL
D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D005820:Genetic Testing; D006801:Humans; D057285:Precision Medicine; D013629:Tamoxifen / Q000494:pharmacology / Q000627:therapeutic use*
D018931:Antineoplastic Agents, Hormonal; D065690:Cytochrome P-450 CYP2D6 Inhibitors; D013629:Tamoxifen; D019389:Cytochrome P-450 CYP2D6